U050 The Utility of Older Generic Medicines in the Current Practice of Dermatology
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
With the expanding portfolio of biologic injectables and newer targeted immunosuppressants the use of older, less expensive therapies has decreased. These newer medicines have improved patient outcomes but have also led to significantly increased costs of care. This is further compounded by a decreased education in residency and therefore comfort level for newer physicians. This session will illustrate that medicines like methotrexate, injectable 5-FU, acitretin, cyclosporine etc. still have a place within the clinical care of dermatologic patients and will focus on the safe and proper use of these medicines.
LEARNING OBJECTIVES
Determine the clinical scenarios where less expensive, older generic therapies can play a role in treating dermatologic disease.
Define patient populations and disease states that are appropriate for medications such as ex. methotrexate, cyclosporine, mycophenolate mofetil and acitretin and those in which these medications are not appropriate for use.
Develop a comfort level with these medications increasing likelihood of use in the practice of cost effective care.
SCHEDULE
9:30 PM
The Utility of Older Generic Medicines in the Current Practice of Dermatology
SPEAKERS
Elizabeth Jones, MD, FAAD
Matthew S Keller, MD, FAAD
Neda Nikbakht, MD, PhD, FAAD
SPEAKER DISCLOSURES
Elizabeth Jones, MD, FAAD
No financial relationships exist with ineligible companies.
Matthew S Keller, MD, FAAD
No financial relationships exist with ineligible companies.
Neda Nikbakht, MD, PhD, FAAD
Helsinn Healthcare – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Krystal Biotech, Inc – Advisory Board(Honoraria); Kyowa Kirin – Advisory Board(Honoraria);